PE20011113A1 - Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina - Google Patents
Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacinaInfo
- Publication number
- PE20011113A1 PE20011113A1 PE2001000206A PE2001000206A PE20011113A1 PE 20011113 A1 PE20011113 A1 PE 20011113A1 PE 2001000206 A PE2001000206 A PE 2001000206A PE 2001000206 A PE2001000206 A PE 2001000206A PE 20011113 A1 PE20011113 A1 PE 20011113A1
- Authority
- PE
- Peru
- Prior art keywords
- formulation
- agent
- less
- weight
- ciprofloxacine
- Prior art date
Links
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003405 ciprofloxacin Drugs 0.000 title abstract 2
- 230000037406 food intake Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 229920003086 cellulose ether Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA FORMULACION DE LIBERACION CONTROLADA QUE COMPRENDE: a) UNA CANTIDAD EFECTIVA DE CIPROFLOXACINA; b) DE 0,1% A 8 % DE UN AGENTE DE VISCOSIDAD TAL COMO GOMA, ETERES DE CELULOSA DE PREFERENCIA GOMA XANTANO E HIDROXIPROPILCELULOSA Y/O UN AGENTE DE GELACION TAL COMO ALGINATO DE SODIO; c) DE 5% A 15% DE UNA AGENTE GENERADOR DE GAS TAL COMO BICARBONATO DE SODIO, CARBONATO DE CALCIO, CARBONATO DE SODIO Y; d) DE 3% A 15% DE UN AGENTE DE EXPANSION TAL COMO POLIVINILPIRROLIDONA , SIENDO TALES PORCENTAJES CON RELACION AL PESO/PESO DEL COMPUESTO. LA CIPROFLOXACINA SE LIBERA MAS DEL 50% DEL MEDICAMENTO EN MENOS DE 4 HORAS Y MAS DEL 60% DEL MEDICAMENTO EN MENOS DE 8 HORAS. LA FORMULACION COMPRENDE DE 100mg A 1000mg DE CIPROFLOXACINA Y EXCIPIENTES EN LA QUE EL PESO TOTAL DE LA FORMULACION CORRESPONDE A MENOS DE 2000mg. LA FORMULACION ES ADMINISTRADA VIA ORAL Y LA LIBERACION CONTROLADA DE CIPROFLOXACIONA SE PRODUCE EN EL ESTOMAGO O PARTE SUPERIOR DEL INTESTINO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51788700A | 2000-03-03 | 2000-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011113A1 true PE20011113A1 (es) | 2001-10-14 |
Family
ID=24061635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000206A PE20011113A1 (es) | 2000-03-03 | 2001-03-01 | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1263409A1 (es) |
| JP (1) | JP2003525229A (es) |
| KR (1) | KR20030009374A (es) |
| CN (1) | CN1420763A (es) |
| AP (2) | AP1485A (es) |
| AR (1) | AR032614A1 (es) |
| AU (1) | AU3589701A (es) |
| BG (1) | BG107055A (es) |
| BR (1) | BR0108958A (es) |
| CA (1) | CA2400950A1 (es) |
| CZ (1) | CZ20022883A3 (es) |
| DO (1) | DOP2001000130A (es) |
| EA (1) | EA200200914A1 (es) |
| EC (1) | ECSP013952A (es) |
| EE (1) | EE200200497A (es) |
| GT (1) | GT200100033A (es) |
| HN (1) | HN2001000038A (es) |
| HR (1) | HRP20020715A2 (es) |
| HU (1) | HUP0204417A3 (es) |
| IL (1) | IL151553A0 (es) |
| IS (1) | IS6532A (es) |
| MX (1) | MXPA02008568A (es) |
| NO (1) | NO20024108L (es) |
| NZ (1) | NZ520927A (es) |
| OA (1) | OA12381A (es) |
| PE (1) | PE20011113A1 (es) |
| PL (1) | PL365071A1 (es) |
| SK (1) | SK12542002A3 (es) |
| WO (1) | WO2001064183A1 (es) |
| YU (1) | YU66202A (es) |
| ZA (1) | ZA200206764B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US20030229101A1 (en) * | 2002-06-06 | 2003-12-11 | Sherman Bernard Charles | Tablets comprising ciprofloxacin hydrochloride |
| DE10351448A1 (de) | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| DE602005007205D1 (de) * | 2005-07-19 | 2008-07-10 | Ethypharm Sa | Gastroretentive Zusammensetzungen und Verfahren zur Herstellung |
| EP1880722B1 (en) * | 2006-07-19 | 2010-03-17 | Tabuk Pharmaceutical Manufacturing Co. | Pharmaceutical compositions of ciprofloxacin |
| US10363288B2 (en) | 2015-01-14 | 2019-07-30 | National Jewish Health | Insulin mimotopes and methods of using the same |
| CA3015400C (en) * | 2016-02-23 | 2024-10-29 | Matripharm International Inc. | DUAL-RATE, HIGH-DRUGGED COMPOSITION |
| AU2017236977B2 (en) | 2016-03-24 | 2022-05-26 | Immunomolecular Therapeutics, Inc. | Methods of treating autoimmune disease |
| US11052060B2 (en) | 2018-02-12 | 2021-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and methods for treating autoimmunity |
| US11013707B2 (en) | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
| CN109806237A (zh) * | 2019-03-13 | 2019-05-28 | 悦康药业集团上海制药有限公司 | 一种乳酸环丙沙星泡腾片及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
| JPH0624959A (ja) * | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
| DE4406424A1 (de) * | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
| DE19839057A1 (de) * | 1998-08-28 | 2000-03-02 | Koch Berthold | Spülluft-Regler für eine Trockenvorrichtung für Druckluft |
| CZ2001901A3 (cs) * | 1998-09-14 | 2001-08-15 | Ranbaxy Laboratories Limited | Farmaceutická kompozice představující systém řízeného dodávání léku pro orální podání, poskytující časovou a místní kontrolu |
-
2001
- 2001-02-28 HU HU0204417A patent/HUP0204417A3/hu unknown
- 2001-02-28 WO PCT/IB2001/000279 patent/WO2001064183A1/en not_active Ceased
- 2001-02-28 CN CN01805998A patent/CN1420763A/zh active Pending
- 2001-02-28 JP JP2001563081A patent/JP2003525229A/ja not_active Withdrawn
- 2001-02-28 CZ CZ20022883A patent/CZ20022883A3/cs unknown
- 2001-02-28 AU AU35897/01A patent/AU3589701A/en not_active Abandoned
- 2001-02-28 IL IL15155301A patent/IL151553A0/xx unknown
- 2001-02-28 SK SK1254-2002A patent/SK12542002A3/sk unknown
- 2001-02-28 AP APAP/P/2002/002627A patent/AP1485A/en active
- 2001-02-28 CA CA002400950A patent/CA2400950A1/en not_active Abandoned
- 2001-02-28 EA EA200200914A patent/EA200200914A1/ru unknown
- 2001-02-28 EE EEP200200497A patent/EE200200497A/xx unknown
- 2001-02-28 YU YU66202A patent/YU66202A/sh unknown
- 2001-02-28 MX MXPA02008568A patent/MXPA02008568A/es unknown
- 2001-02-28 AR ARP010100957A patent/AR032614A1/es not_active Application Discontinuation
- 2001-02-28 AP APAP/P/2001/002084A patent/AP2001002084A0/en unknown
- 2001-02-28 PL PL01365071A patent/PL365071A1/xx not_active Application Discontinuation
- 2001-02-28 NZ NZ520927A patent/NZ520927A/xx unknown
- 2001-02-28 EP EP01908038A patent/EP1263409A1/en not_active Withdrawn
- 2001-02-28 KR KR1020027011441A patent/KR20030009374A/ko not_active Ceased
- 2001-02-28 OA OA1200200267A patent/OA12381A/en unknown
- 2001-02-28 BR BR0108958-7A patent/BR0108958A/pt not_active IP Right Cessation
- 2001-02-28 HR HRP20020715 patent/HRP20020715A2/hr not_active Application Discontinuation
- 2001-03-01 GT GT200100033A patent/GT200100033A/es unknown
- 2001-03-01 EC EC2001003952A patent/ECSP013952A/es unknown
- 2001-03-01 PE PE2001000206A patent/PE20011113A1/es not_active Application Discontinuation
- 2001-03-02 HN HN2001000038A patent/HN2001000038A/es unknown
- 2001-03-02 DO DO2001000130A patent/DOP2001000130A/es unknown
-
2002
- 2002-08-23 ZA ZA200206764A patent/ZA200206764B/en unknown
- 2002-08-28 NO NO20024108A patent/NO20024108L/no unknown
- 2002-08-28 IS IS6532A patent/IS6532A/is unknown
- 2002-09-02 BG BG107055A patent/BG107055A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2002002627A0 (en) | 2002-09-30 |
| WO2001064183A1 (en) | 2001-09-07 |
| CN1420763A (zh) | 2003-05-28 |
| IS6532A (is) | 2002-08-28 |
| YU66202A (sh) | 2005-09-19 |
| ZA200206764B (en) | 2003-03-04 |
| JP2003525229A (ja) | 2003-08-26 |
| NO20024108D0 (no) | 2002-08-28 |
| SK12542002A3 (sk) | 2003-05-02 |
| ECSP013952A (es) | 2002-04-23 |
| BR0108958A (pt) | 2003-09-30 |
| CA2400950A1 (en) | 2001-09-07 |
| DOP2001000130A (es) | 2004-03-31 |
| AU3589701A (en) | 2001-09-12 |
| NO20024108L (no) | 2002-10-25 |
| NZ520927A (en) | 2003-06-30 |
| EA200200914A1 (ru) | 2003-02-27 |
| HUP0204417A3 (en) | 2005-03-29 |
| IL151553A0 (en) | 2003-04-10 |
| EP1263409A1 (en) | 2002-12-11 |
| KR20030009374A (ko) | 2003-01-29 |
| OA12381A (en) | 2004-09-06 |
| AP1485A (en) | 2005-10-31 |
| AR032614A1 (es) | 2003-11-19 |
| AP2001002084A0 (en) | 2001-03-31 |
| CZ20022883A3 (cs) | 2003-04-16 |
| HN2001000038A (es) | 2005-03-23 |
| EE200200497A (et) | 2004-02-16 |
| BG107055A (bg) | 2003-06-30 |
| PL365071A1 (en) | 2004-12-27 |
| HRP20020715A2 (en) | 2004-12-31 |
| MXPA02008568A (es) | 2003-02-24 |
| GT200100033A (es) | 2001-10-25 |
| HUP0204417A2 (en) | 2003-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR022672A1 (es) | Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga | |
| ES2251494T3 (es) | Formulacion de accion rapida. | |
| PL1898876T3 (pl) | Preparaty mukoadhezyjne zawierające ksyloglukan, użyteczne w wyrobach medycznych i preparatach farmaceutycznych | |
| YU19501A (sh) | Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu | |
| BR0113626A (pt) | Formulações de liberação sustentada para secretores de hormÈnio do crescimento | |
| PE20011113A1 (es) | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina | |
| CO6251259A2 (es) | Formulaciones farmaceuticas de estriol en baja dosis | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| BR9916224A (pt) | Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola | |
| NZ511900A (en) | Sustained release matrix systems for highly soluble drugs | |
| CL2004000899A1 (es) | Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion. | |
| NO962752L (no) | Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose | |
| BR0307320A (pt) | Sistema de liberação osmótico | |
| BR0312640A (pt) | Formulação contra mycoplasma gallisepticum | |
| ES2113136T3 (es) | Composiciones farmaceuticas de gemfibrozil y procedimiento para su preparacion. | |
| MX9704043A (es) | Surtido de farmaco de liberacion sostenida empleando una goma de hidrocoloide en polvo obtenible a partir de plantas superiores. | |
| UY26176A1 (es) | Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas. | |
| ES2238497T3 (es) | Granulado de ribavirina para la obtencion de comprimidos peliculados. | |
| BR0318167A (pt) | formulação de liberação controlada contendo um material hidrofóbico como o agente de liberação controlada | |
| UY26605A1 (es) | Sistema de administración oral controlada para la ingestión diaria de ciprofloxacina | |
| BR0300434A (pt) | Composição farmacêutica oral, utilizada como antiespasmódico geral do músculo liso com aplicações biliares, digestivas, urinárias e ginecológicas, e no tratamento da cólica intestinal moderada a severa, e, uso da mesma | |
| JO2440B1 (en) | Formulation of oral pharmaceutical polymers for controlled release of terbutalate sulfate. | |
| BR0207299A (pt) | Composição farmacêutica, solução aquosa e métodos para fabricar e para preparar uma composição, para instruir um humano a ingerir uma composição farmacêutica de liberação imediata e para tratar um humano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |